Oculis SA

Swiss Biotech Association

Member

Oculis S.A. is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.

Products, services, technology

OCS-01 being developed in DME and Post-ocular surgery inflammation;
OCS-02 being developed for Dry Eye Disease and Uveitis;
Pre-clinical candidates for retinal disorders and for ocular inflammation

http://www.oculis.com
+41 21 711 39 70
louie-anne.gauthier@oculis.com
Louie-Anne Gauthier

Location

EPFL, 1015 Lausanne, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

plusbiome AG

plusbiome AG is a Swiss startup company working at the interface of digital health and the microbiome. We design and market customised probiotics that truly support customers and their well-being,. Customers also profit from accompanying Apps.
4057 Basel

Member

SOMAGENETIX AG

Somagenetix is a Spin-off from the Univ of Zurich leveraging scientific, clinical and commercial expertise to solve unmet medical needs through gene therapy. We aim at becoming a leading gene therapy company with first-in-class and best-in-class treatment for phagocyte-related disorders.
8047 Zürich

Member

Adoram Therapeutics SA

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).
1212 Grand-Lancy

Member